Akebia Therapeutics, Inc.
AKBAAkebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. The company's lead product, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor intended to treat anemia associated with chronic kidney disease. Akebia aims to address unmet medical needs in renal conditions through innovative treatments.
Company News
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts say these are penny stocks to buy but are they worth the risk? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
